Melanoma
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
- Details
ClinicalTrials.gov ID:
NCT06246916
Diagnosis Type:
NA
USOR Number:
- Address
,
P: